Back
ESC Premium Access

Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy

Session: Cardiomyopathies
Topic: Pharmacologic therapy
Speaker: Professor C. MacRae (Boston, US)
Event: ESC Congress 2016

Congress Presentation

Add to my library

Like

About the speaker

Professor Calum MacRae

Harvard Medical School, Boston (United States of America)
6 presentations
0 follower

6 more presentations in this session

Gender differences in the development of CMR abnormalities and cardiac complications: a multicentric prospective study in a large cohort of thalassemia major patients

Speaker: Doctor A. Pepe (Pisa, IT)

Access
Abstract
Slides
Like
Thumbnail

Long time clinical course of cardiac sarcoidosis: retrospective cohort analysis in Japan

Speaker: Doctor T. Nagayama (Osaka, JP)

Access
Abstract
Slides
Like
Thumbnail

Incident heart failure in patients with rheumatoid arthritis: a nationwide cohort study

Speaker: Doctor U. Khalid (Hellerup, DK)

Access
Abstract
Slides
Like
Thumbnail

Cardiomyocyte bulking is a novel predictor of left ventricular reverse remodeling in patients with dilated cardiomyopathy

Speaker: Mr K. Fukaya (Nagoya, JP)

Access
Abstract
Like
Thumbnail

Eosinophilic myocarditis in patients on dobutamine therapy: an underappreciated but not uncommon phenomenon

Speaker: Doctor M. Barrett (Dublin, IE)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Cardiomyopathies

Speakers: Professor C. MacRae, Doctor A. Pepe, Doctor T. Nagayama, Doctor U. Khalid, Mr K. Fukaya...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources